TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06614231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab Combined With Chemotherapy
Description: Tislelizumab 200mg Q3W，Platinum-containing dual drug chemotherapy
Study: NCT06614244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Description: OIT in DOPA group will be implemented as follows. Both the first micro-dose of the offending food and the subsequent micro-increments will be administered at home. Any interruptions and resumptions of OIT, due to intercurrent events (e.g. infections), will be managed via email with or without medical visit via video call. Patients will be provided with ondansetron (sublingual film) and instructions for its use. An explanatory letter will also be provided in case of need for emergency room access.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Culprit food elimination diet
Description: The Diet group consists of a population of children affected by acute persistent FPIES subjected to the traditional measure, i.e. the elimination diet of the incriminated food.
Study: NCT06687460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief electrical stimulation
Description: During the nerve micro-reconstruction surgery, electrical stimulation is given to the distal end of the damaged nerve for 30 minutes.
Study: NCT05325632

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2 pulsed DC1
Description: Vaccine will be administered weekly for 6 weeks. Boosters will be given at months 6, 9 and 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8mg/kg IV Trastuzumab will be given week 1, followed by 6 mg/kg on subsequent cycles every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8mg/kg IV Trastuzumab will be given week 1, followed by 6 mg/kg on subsequent cycles every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8mg/kg IV Trastuzumab will be given week 1, followed by 6 mg/kg on subsequent cycles every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8mg/kg IV Trastuzumab will be given week 1, followed by 6 mg/kg on subsequent cycles every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg IV Pertuzumab will be given week 1, followed by 420 mg on subsequent cycles every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg IV Pertuzumab will be given week 1, followed by 420 mg on subsequent cycles every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg IV Pertuzumab will be given week 1, followed by 420 mg on subsequent cycles every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg IV Pertuzumab will be given week 1, followed by 420 mg on subsequent cycles every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 IV paclitaxel will be given weekly weeks 7-18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 IV paclitaxel will be given weekly weeks 7-18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 IV paclitaxel will be given weekly weeks 7-18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 IV paclitaxel will be given weekly weeks 7-18

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection surgery
Description: After week 18, participants will undergo standard of care resection surgery.
Study: NCT06687460

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no nerve electrical stimulation
Description: only nerve microsurgical reconstruction, no nerve electrical stimulation
Study: NCT06690151

Intervention type: BEHAVIORAL
Intervention: Neurodevelopmental assessment (Bayley-IV)
Description: Assessment of developmental delays through administration of the Bayley-4 test by a neuropsychologist

Intervention type: OTHER
Intervention: Biological sampling
Description: The samples to be collected at delivery will include:~* A 4 ml maternal blood sample in an EDTA tube for lipidomic and metabolomic analyses at delivery~* A 6 ml maternal blood sample in an EDTA tube (2 tubes of 3 ml) for genetic analysis~* A 4 ml venous cord blood sample in an EDTA tube for transcriptomic and epigenetic analysis; and a 2 ml EDTA tube for metabolomic/lipidomic analysis~* Samples from fresh placenta for transcriptomic, epigenetic, metabolomic, and lipidomic analyses~* A meconium sample collected as soon as possible after birth in a dry tube for microbiome analysis~During hospitalization for the cardiac surgery:~* Genome analysis samples will be collected from the father and the infant. These samples will be taken in two EDTA tubes of 3 ml each.~* Perioperative neurobiomarker samples will be collected (one EDTA tube of 500 μL preoperatively and postoperatively on Day 1 and Day 2).~At 1 month, a stool sample will be collected from the infants for microbiome analysis.

Intervention type: BEHAVIORAL
Intervention: ELFE dietary questionnaire
Description: Questionnaire on diet and lifestyle during pregnancy (only for the mother)

Intervention type: BEHAVIORAL
Intervention: Post-Traumatic Stress Questionnaire IES-R (Impact of Event Scale - Revised)
Description: The IES-R is a 22-item self-report measure (for DSM-IV) that assesses subjective distress caused by traumatic events.

Intervention type: OTHER
Intervention: Data collection for the study (Cardiovascular, developemental, fetal, pregnancy, MRI)
Description: * Cardiovascular follow-up data collection~* Developmental follow-up data collection~* Collection of postoperative brain MRI data, scheduled between Day 5 post-surgery and the end of the hospital stay~* Collection of data on pregnancy exposure, obstetric events, and delivery data.~* Collection of fetal ultrasound data (T2 and T3).~* Collection of fetal echocardiography data (T2 and T3).
Study: NCT06627907

Intervention type: OTHER
Intervention: fluid challenge
Description: The study protocol is started during a period of intraoperative hemodynamic stability, as previously defined (i.e. change in mean arterial pressure of less than 10% during 5 minutes \[32, 33\]). The study protocol is was the following: 1) a set of measurements was recorded (T0) at a baseline 2) (T1) after one minute the EEOT is then performed by stopping the mechanical ventilation for 30 seconds (T2 - end of the EEOT test); 3) (T3) a FC of overall 6 mL/Kg of crystalloid solution is infused over 10 minutes (T4 end of the FC). The attending anesthetist is allowed to interrupt the protocol at any stage for either hemodynamic instability or any other adverse effects requiring urgent treatment.~The protocol is entirely intraoperative and data collections ends after FC administration. No follow-up is needed.~The mentioned timepoints T0 - T1 - T2, corresponding to intrapeortive data recording points are also the endpoints of the study. At each specific timepoint, a marker is added to the M

Intervention type: DIAGNOSTIC_TEST
Intervention: end-expiratory occlusion test
Description: The study protocol is started during a period of intraoperative hemodynamic stability, as previously defined (i.e. change in mean arterial pressure of less than 10% during 5 minutes \[32, 33\]). The study protocol is was the following: 1) a set of measurements was recorded (T0) at a baseline 2) (T1) after one minute the EEOT is then performed by stopping the mechanical ventilation for 30 seconds (T2 - end of the EEOT test); 3) (T3) a FC of overall 6 mL/Kg of crystalloid solution is infused over 10 minutes (T4 end of the FC). The attending anesthetist is allowed to interrupt the protocol at any stage for either hemodynamic instability or any other adverse effects requiring urgent treatment.~The protocol is entirely intraoperative and data collections ends after FC administration. No follow-up is needed.~The mentioned timepoints T0 - T1 - T2, corresponding to intrapeortive data recording points are also the endpoints of the study. At each specific timepoint, a marker is added to the M
Study: NCT04895345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT05348122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103,QW
Description: TG103 injection will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo,Q2W
Description: Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo,QW
Description: Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide,QW
Description: Dulaglutide will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
Study: NCT05392283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AERO vacuum cupping device
Description: The treatment consists of 5 sessions (approx. 30 min) of vacuum massage. The vacuum pump provided by the device provides a type of vacuum massage, that can be adjusted according to applied suction and air flow. The resulting massage technique provides a type of soft tissue manipulation similar to the ancient traditional medicine technique of cupping. Nonetheless, this automated technique allows for more precise determination of the massage characteristics.
Study: NCT06053372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apple Watch
Description: Wearable monitor for heart rate and arrhythmia detection
Study: NCT06564740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: UC-MSC transplantation will be administered twice to each patient in the study group via the hepatic artery: the first transplantation will be performed post-surgery at the beginning, and the second one will be performed 6 months later, with a dose of 1 million UC-MSC/kg.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: In this group, UC-MSC will not be administered. This group serves as a passive control. The standard treatments that are routinely provided to these patients will continue to be administered.
Study: NCT05022654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: Administered by intravenous drip every 2 weeks (Q2W). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: The dose of irinotecan was 180mg/m2 Q2W, the infusion method was according to the drug instructions, SI-B001 and irinotecan were used on the same day, and irinotecan was injected after SI-B001 infusion.
Study: NCT06114628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: Oral daily dosage of 20mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: Oral daily dosage of 20mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: Oral daily dosage of 20mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: Oral daily dosage of 20mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: Oral daily dosage of 20mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: Oral daily dosage of 1000mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: Oral daily dosage of 1000mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: Oral daily dosage of 1000mg.
Study: NCT05317195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-4
Description: NP-4; 3.6 mg nicotine; pH 8.0; moisture 30

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP-4
Description: NP-4; 3.6 mg nicotine; pH 8.0; moisture 30
Study: NCT05741307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis application
Description: The Hypnotidoo application offers screenless self-hypnosis sessions for 5-12 year olds. Each session lasts 6 to 8 minutes and focuses on one of the following themes: stress and anxiety, sleep, daily troubles and discomforts, hypersensitivity, hyperactivity and difficulty concentrating, self-confidence, difficult life events, anger. Each session begins with breathing and refocusing work, followed by self-hypnosis through stories and metaphors suitable for children.~The application will be used by patients in the context of research for 6 weeks, 5 days out of 7 in parallel with the usual treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis application
Description: The Hypnotidoo application offers screenless self-hypnosis sessions for 5-12 year olds. Each session lasts 6 to 8 minutes and focuses on one of the following themes: stress and anxiety, sleep, daily troubles and discomforts, hypersensitivity, hyperactivity and difficulty concentrating, self-confidence, difficult life events, anger. Each session begins with breathing and refocusing work, followed by self-hypnosis through stories and metaphors suitable for children.~The application will be used by patients in the context of research for 6 weeks, 5 days out of 7 in parallel with the usual treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Before and after (at T0, T1, T2 and T3) the 6-week period of use of the application and a wash-out period of 2 weeks (= usual treatment only), self- and hetero-questionnaires which constitute the gold standard for evaluating the symptoms of inattention and anxiety are proposed: Conners III, Child Behavior Checklist (CBCL) and Revised-Children's Manifest Anxiety Scale (R-CMAS).~* T0: inclusion~* T1: 6 weeks after T0 (inclusion)~* T2: 2 weeks after T1~* T3: 6 weeks after T2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Before and after (at T0, T1, T2 and T3) the 6-week period of use of the application and a wash-out period of 2 weeks (= usual treatment only), self- and hetero-questionnaires which constitute the gold standard for evaluating the symptoms of inattention and anxiety are proposed: Conners III, Child Behavior Checklist (CBCL) and Revised-Children's Manifest Anxiety Scale (R-CMAS).~* T0: inclusion~* T1: 6 weeks after T0 (inclusion)~* T2: 2 weeks after T1~* T3: 6 weeks after T2
Study: NCT04895345

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy
Description: Intensity-modulated conformal radiotherapy (IMRT) is a kind of three dimensional conformal radiotherapy, which requires the dose intensity in the radiation field to be adjusted according to certain requirements.
Study: NCT04159506

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mindfulness, emotion didactics, interpersonal skills, experiential learning
Description: mindfulness interventions involve body scanning, deep breathing, and muscle relaxation. Emotion didactics focus on emotion recognition and regulation. Interpersonal skill development looks at how to use emotion regulation to improve social functioning. Experiential learning means learning either through interactions with horses or via team-building activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness, emotion didactics, interpersonal skills, experiential learning
Description: mindfulness interventions involve body scanning, deep breathing, and muscle relaxation. Emotion didactics focus on emotion recognition and regulation. Interpersonal skill development looks at how to use emotion regulation to improve social functioning. Experiential learning means learning either through interactions with horses or via team-building activities.
Study: NCT05325632

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection surgery
Description: After week 18, participants will undergo standard of care resection surgery.
Study: NCT06132841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6234
Description: Participants will receive repeated doses of AZD6234 as a solution via SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6234
Description: Participants will receive repeated doses of AZD6234 as a solution via SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6234
Description: Participants will receive repeated doses of AZD6234 as a solution via SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching volumes of the placebo as a solution via SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching volumes of the placebo as a solution via SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching volumes of the placebo as a solution via SC
Study: NCT06243484

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TOTUM-070
Description: 12 weeks of TOTUM-070 supplementation with Placebo (blinded arms)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: 8 capsules per day to consume orally in two intakes
Study: NCT05421871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spinal Stabilization Exercises
Description: Spinal Stabilization Exercises technique

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maitland Mobilization Along With Laser Therapy
Description: Maitland Mobilization Along With Laser Therapy technique
Study: NCT04836312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soft Commitment Device
Description: Patients randomized to the commitment device arm will be asked to visit the Way to Health platform. There, they will identify a support person, a family or friend who they speak to frequently and who is invested in their health. They will then complete a series of questions intended to create implementation intentions. Specifically, they will pick a time for their fast to begin each 24-hour period and a time for their fast to end. They will also develop strategies to deal with hunger arising during a fast period. After this process, they will sign a contract pledging to adhere to the 16:8 time-restricted feeding dietary pattern, and acknowledging that their support person will receive a copy of the contract and weekly updates about their adherence to the regimen.
Study: NCT05476458

Intervention type: RADIATION
Intervention: White Light Imaging
Description: white light imaging is often the preferred option for poem surgery due to its effective results. However, it also comes with some drawbacks that make it difficult to identify areas of bleeding, unlike RDI, WLI cannot enhance the visibility of deep vessels This can lead to longer haemostasis time as the physician must wait for a longer period before stopping the bleeding. This can make it challenging as it may lead to excessive bleeding. This makes RDI a potential solution for those seeking a more accurate approach to treatment.

Intervention type: RADIATION
Intervention: Red Light Imaging
Description: Red dichromatic imaging (RDI) is a next-generation image enhancement technique which works by employing green, amber and red wavelengths. Greenlight(520-550nm) can visualize small blood vessels in superficial tissue without extending deep into the mucosa. Amber(595-610nm) and red light (620-640nm) can penetrate deep into the tissue owing to low scattering property. The blood vessels in the deeper tissues absorb the amber light because of strong affinity with hemoglobin. Even though red light can penetrate deep into the tissue, it is weakly absorbed by hemoglobin. Hence the reflected light contains red light and amber light without attenuation.
Study: NCT05109845

Intervention type: DIAGNOSTIC_TEST
Intervention: Spheres & Shield Maze Task
Description: A VR environment that consists of a maze that the user must solve by moving through space. The movement is done by combining a touchpad with front-facing orientation.~Different hazards will present throughout the maze, with time penalty, energy loss, and certain consequences, such as narrow walkways from which the player can fall (Figure 1) lightning clouds that strike in intervals, flying insects (Figure 2), or locked rooms (Figure 3). The user can also make use of a shield that allows moving through lightning and insects without penalty at the cost of being unable to gather green orbs (Figure 2). When used, the shield requires a recharge time, so it is a limited resource that the player must optimize. Hazards may also be avoided completely by choosing another path through the labyrinth, however completion of the maze requires traversal of a minimum number of hazards.

Intervention type: DIAGNOSTIC_TEST
Intervention: Spheres & Shield Maze Task
Description: A VR environment that consists of a maze that the user must solve by moving through space. The movement is done by combining a touchpad with front-facing orientation.~Different hazards will present throughout the maze, with time penalty, energy loss, and certain consequences, such as narrow walkways from which the player can fall (Figure 1) lightning clouds that strike in intervals, flying insects (Figure 2), or locked rooms (Figure 3). The user can also make use of a shield that allows moving through lightning and insects without penalty at the cost of being unable to gather green orbs (Figure 2). When used, the shield requires a recharge time, so it is a limited resource that the player must optimize. Hazards may also be avoided completely by choosing another path through the labyrinth, however completion of the maze requires traversal of a minimum number of hazards.

Intervention type: DIAGNOSTIC_TEST
Intervention: Spheres & Shield Maze Task
Description: A VR environment that consists of a maze that the user must solve by moving through space. The movement is done by combining a touchpad with front-facing orientation.~Different hazards will present throughout the maze, with time penalty, energy loss, and certain consequences, such as narrow walkways from which the player can fall (Figure 1) lightning clouds that strike in intervals, flying insects (Figure 2), or locked rooms (Figure 3). The user can also make use of a shield that allows moving through lightning and insects without penalty at the cost of being unable to gather green orbs (Figure 2). When used, the shield requires a recharge time, so it is a limited resource that the player must optimize. Hazards may also be avoided completely by choosing another path through the labyrinth, however completion of the maze requires traversal of a minimum number of hazards.
Study: NCT06319261

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: guided biofilm therapy
Description: Removing plaque and calculus by initially detecting it with a disclosing agent followed by the use of air abrasive powder for the removal of supra and subgingival plaque.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: root surface debridement
Description: Removing plaque and calculus by conventional root surface debridement